Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition

Cancer Discovery

Volumn 4, Issue 8, 2014, Pages 896-904

  González Billalabeitia, Enrique ^a,b,j   Seitzer, Nina ^a,b   Song, Su Jung ^a,b   Song, Min Sup ^a,b   Patnaik, Akash ^a,c,d   Liu, Xue Song ^a,b   Epping, Mirjam T ^a,b   Papa, Antonella ^a,b   Hobbs, Robin M ^a,b   Chen, Ming ^a,b   Lunardi, Andrea ^a,b   Ng, Christopher ^a,b   Webster, Kaitlyn A ^a,b   Signoretti, Sabina ^e,h   Loda, Massimo ^f,g,h,i   Asara, John M ^a   Nardella, Caterina ^a,b,e   Clohessy, John G ^a,b,e   Cantley, Lewis C ^a,d   Pandolfi, Pier Paolo ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Department of Medicine ^*

^c Department of Medicine   (United States)

^d Divisions of Signal Transduction Department of Medicine

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g Center for Molecular Oncologic Pathology

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^j HOSPITAL MORALES MESEGUER   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUPARLISIB; DIMETHYL SULFOXIDE; METHYLCELLULOSE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG; ELAFIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PI3 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DRUG SENSITIVITY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MALE; MASS SPECTROMETRY; MOUSE; NICK END LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SENESCENCE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL AGING; DRUG EFFECTS; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL AGING; CELL LINE, TUMOR; ELAFIN; HUMANS; MALE; MICE; MOLECULAR TARGETED THERAPY; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905493584     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0230     Document Type: Article

References (23)

1. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med 2007;357:2696-705.
2. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178:2359-65.
3. Li J. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
4. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
5. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012;13:283-96.
6. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19.
7. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74.
8. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19:348-55.
9. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998;95:15587-91.
10. Puc J, Keniry M, Li H, Pandita T, Choudhury A, Memeo L, et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005;7:193-204.
11. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim J-S, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009;1:315-22.
12. Bryant H E, Schultz N, Thomas H D, Parker K M, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
13. Chen Z, Trotman LC, Shaffer D, Lin H-K, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nat Cell Biol 2005;436:725-30.
14. Marte BM, Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 1997;22: 355-8.
15. Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease. Cell Signal 2011;23:1515-27.
16. Tapodi A. Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress. J Biol Chem 2005;280:35767-75.
17. Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012;2:1048-63.
18. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PMJ, Dartois C, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008;68:6598-607.
19. Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J, et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci 2008;105:9739-44.
20. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer 2013;45:747-55.
21. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. Plos Biol 2003;1:e9.
22. Nastiuk KL, Liu H, Hamamura M, Muftuler LT, Nalcioglu O, Krolewski JJ. In vivo MRI volumetric measurement of prostate regression and growth in mice. BMC Urol 2007;7:12.
23. Park J-H, Walls JE, Galvez JJ, Kim M, Abate-Shen C, Shen MM, et al. Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol 2010;161:727-35.